NO990003D0 - Administreringssystem for genterapi - Google Patents

Administreringssystem for genterapi

Info

Publication number
NO990003D0
NO990003D0 NO990003A NO990003A NO990003D0 NO 990003 D0 NO990003 D0 NO 990003D0 NO 990003 A NO990003 A NO 990003A NO 990003 A NO990003 A NO 990003A NO 990003 D0 NO990003 D0 NO 990003D0
Authority
NO
Norway
Prior art keywords
management system
gene therapy
therapy management
dna
positively charged
Prior art date
Application number
NO990003A
Other languages
English (en)
Norwegian (no)
Other versions
NO990003L (no
Inventor
Lisbeth Illum
Original Assignee
Danbiosyst Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9614441.5A external-priority patent/GB9614441D0/en
Priority claimed from GBGB9614471.2A external-priority patent/GB9614471D0/en
Application filed by Danbiosyst Uk Ltd filed Critical Danbiosyst Uk Ltd
Publication of NO990003D0 publication Critical patent/NO990003D0/no
Publication of NO990003L publication Critical patent/NO990003L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Medical Informatics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Electrotherapy Devices (AREA)
  • Saccharide Compounds (AREA)
NO990003A 1996-07-10 1999-01-04 Administreringssystem for genterapi NO990003L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9614441.5A GB9614441D0 (en) 1996-07-10 1996-07-10 Gene therapy delivery system for targeting to the lung endothelia
GBGB9614471.2A GB9614471D0 (en) 1996-07-10 1996-07-10 Gene delivery to epithelial cells
PCT/GB1997/001860 WO1998001161A2 (en) 1996-07-10 1997-07-10 Gene therapy delivery system for targeting to endothelia

Publications (2)

Publication Number Publication Date
NO990003D0 true NO990003D0 (no) 1999-01-04
NO990003L NO990003L (no) 1999-01-04

Family

ID=26309674

Family Applications (2)

Application Number Title Priority Date Filing Date
NO990003A NO990003L (no) 1996-07-10 1999-01-04 Administreringssystem for genterapi
NO990002A NO990002D0 (no) 1996-07-10 1999-01-04 Blandinger for administrasjon av gener

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO990002A NO990002D0 (no) 1996-07-10 1999-01-04 Blandinger for administrasjon av gener

Country Status (13)

Country Link
EP (2) EP0994726B1 (de)
JP (2) JP2000514086A (de)
KR (2) KR20000067855A (de)
AT (2) ATE216265T1 (de)
AU (2) AU720989B2 (de)
CA (2) CA2257300A1 (de)
DE (2) DE69712110T2 (de)
DK (1) DK0986404T3 (de)
ES (2) ES2175433T3 (de)
GB (2) GB2330534B (de)
NO (2) NO990003L (de)
PT (2) PT994726E (de)
WO (2) WO1998001161A2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
JPH11246392A (ja) * 1998-03-03 1999-09-14 Makoto Otsuka 経口用固形製剤
AU3898699A (en) * 1998-05-13 1999-11-29 Regents Of The University Of Michigan, The Sustained dna delivery from structural matrices
JP4360758B2 (ja) 1999-04-08 2009-11-11 ジェネンテック・インコーポレーテッド 逆の電荷のポリペプチド類をベースにした組成物
DE19940795A1 (de) * 1999-08-27 2001-03-01 Lohmann Therapie Syst Lts Schnellzerfallende Pellets auf der Basis von Chitosan
SE9904121D0 (sv) * 1999-11-15 1999-11-15 Gustaf Jederstroem Hydrophobe biomolecular structure
DE59910671D1 (de) * 1999-11-18 2004-11-04 Cognis Iberia Sl Mikrokapseln
FR2801811B1 (fr) * 1999-12-06 2002-05-03 Gerard Habar Procede de fabrication de microcapsules portant des charges cationiques
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
AU8737501A (en) * 2000-09-14 2002-03-26 Austin Research Inst Composition comprising immunogenic microparticles
CA2457027C (en) 2001-08-16 2011-10-11 Medical Research Council Chitin microparticles and their medical uses
CA2462593A1 (en) * 2001-10-03 2003-04-10 Kam W. Leong Compositions for oral gene therapy and methods of using same
KR100958235B1 (ko) 2001-12-19 2010-05-17 노바르티스 아게 아미노글리코시드의 폐 전달
NO317653B1 (no) 2002-05-03 2004-11-29 Stiftelsen Biopolymer Formulering som omfatter komplekser av kitosanoligomerer og nukleinsyre, fremgangsmate for a fremstille formuleringen samt anvendelser derav.
WO2004006893A1 (en) * 2002-07-15 2004-01-22 Feyecon Development & Implementation B.V. Method for particle precipitation using near-critical and supercritical antisolvents
US20040014698A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent
US20040048260A1 (en) * 2002-09-10 2004-03-11 Fu-Hsiung Chang Transfection of nucleic acid
CA2549994A1 (en) * 2002-12-18 2004-08-12 Hough Ear Institute Otologic nanotechnology
US8651113B2 (en) 2003-06-18 2014-02-18 Swr&D Inc. Magnetically responsive nanoparticle therapeutic constructs and methods of making and using
US7344491B1 (en) 2003-11-26 2008-03-18 Nanobiomagnetics, Inc. Method and apparatus for improving hearing
US7723311B2 (en) 2003-06-18 2010-05-25 Nanobiomagnetics, Inc. Delivery of bioactive substances to target cells
DE10329087B4 (de) 2003-06-27 2014-02-13 Biomedical International R + D Gmbh Antigenhaltige Mikrosphären zur Allergietherapie
GB0315632D0 (en) 2003-07-04 2003-08-13 West Pharm Serv Drug Res Ltd Pharmaceutical formulations
JP4674288B2 (ja) * 2004-03-31 2011-04-20 恵雄 岡畑 歯科用材料。
US7282194B2 (en) * 2004-10-05 2007-10-16 Gp Medical, Inc. Nanoparticles for protein drug delivery
AU2007285472B2 (en) * 2006-03-30 2013-10-24 Engene, Inc. Non-viral compositions and methods for transfecting gut cells in vivo
CN101415405A (zh) * 2006-04-04 2009-04-22 Stc.Unm公司 用于药物递送的可溶胀颗粒
WO2009006905A1 (en) * 2007-07-06 2009-01-15 Aarhus Universitet Dehydrated chitosan nanoparticles
US8722646B2 (en) * 2007-09-28 2014-05-13 Engene, Inc. High concentration chitosan-nucleic acid polyplex compositions
KR20110028631A (ko) * 2008-07-01 2011-03-21 닛토덴코 가부시키가이샤 표면 피복 미립자의 의약 조성물
CN101869704A (zh) * 2010-06-08 2010-10-27 中国药科大学 单剂免疫破伤风类毒素阳离子葡聚糖微球及其制备方法
US8802076B2 (en) 2010-10-04 2014-08-12 Duke University Compositions and methods for modulating an immune response
WO2021150997A2 (en) * 2020-01-22 2021-07-29 Engene, Inc. Localized expression of therapeutic nucleic acids in lung epithelial cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046750A (en) * 1974-09-30 1977-09-06 California Institute Of Technology Ionene modified small polymeric beads
JPH03198782A (ja) * 1989-12-27 1991-08-29 Bitamin Kenkyusho:Kk 遺伝子導入用キャリアー、該キャリアーと遺伝子との複合体及び細胞への遺伝子導入法
US5972600A (en) * 1992-04-03 1999-10-26 The Regents Of The University Of California Separation of active complexes
AU2946295A (en) * 1994-06-27 1996-01-19 Johns Hopkins University, The Targeted gene delivery system
GB9416884D0 (en) * 1994-08-20 1994-10-12 Danbiosyst Uk Drug delivery compositions
FR2724935B1 (fr) * 1994-09-27 1996-12-20 Centre Nat Rech Scient Compositions nanoparticulaires contenant des derives nucleotidiques, leur preparation et leur emploi en therapeutique
KR960016882A (ko) * 1994-11-01 1996-06-17 강재헌 치주염치료를 위한 서방출형 생분해성 제제
ATE252894T1 (de) * 1995-01-05 2003-11-15 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung

Also Published As

Publication number Publication date
KR20000067855A (ko) 2000-11-25
PT994726E (pt) 2002-09-30
GB9900048D0 (en) 1999-02-24
GB2330534B (en) 2000-09-06
WO1998001161A3 (en) 1998-03-12
ATE216265T1 (de) 2002-05-15
ES2175433T3 (es) 2002-11-16
ATE216264T1 (de) 2002-05-15
NO990002L (no) 1999-01-04
GB9900054D0 (en) 1999-02-24
EP0994726A2 (de) 2000-04-26
DE69712108T2 (de) 2002-12-12
WO1998001160A2 (en) 1998-01-15
PT986404E (pt) 2002-09-30
WO1998001161A2 (en) 1998-01-15
DE69712110T2 (de) 2002-12-12
CA2257408A1 (en) 1998-01-15
AU3454697A (en) 1998-02-02
AU726518C (en) 2002-01-03
WO1998001160A3 (en) 1998-03-05
DE69712110D1 (de) 2002-05-23
CA2257300A1 (en) 1998-01-15
KR20000023716A (ko) 2000-04-25
ES2175434T3 (es) 2002-11-16
AU720989B2 (en) 2000-06-22
EP0986404B1 (de) 2002-04-17
JP2000514086A (ja) 2000-10-24
GB2330534A (en) 1999-04-28
JP2001500109A (ja) 2001-01-09
DE69712108D1 (de) 2002-05-23
NO990003L (no) 1999-01-04
DK0986404T3 (da) 2002-05-13
AU3454597A (en) 1998-02-02
AU726518B2 (en) 2000-11-09
EP0994726B1 (de) 2002-04-17
EP0986404A2 (de) 2000-03-22
NO990002D0 (no) 1999-01-04
GB2330532A (en) 1999-04-28

Similar Documents

Publication Publication Date Title
NO990003D0 (no) Administreringssystem for genterapi
ES2243229T3 (es) Formulaciones de particulas de hidrogel.
ATE182175T1 (de) Verbesserte exotoxine aus pseudomonas mit geringer toxität bei tieren und hoher zelltötender aktivität
IL132156A0 (en) Neoglycoproteins
BR9703417A (pt) Processo para a fabricação de um suplemento de reção animal sobre base de caldo de fermentação
CA2212537A1 (en) Therapeutic inhibitor of vascular smooth muscle cells
PT868505E (pt) Inducao condrogenica in vitro de celulas estaminais mesenquimais humanas
DE69808402D1 (de) Arzneimittel zur Behandlung von durch Hernie gestörter intervertebraler Bandscheibe
EP0993831A3 (de) Komponente und Zusammensetzungen zur Verabreichung von Wirkstoffen
ATE234080T1 (de) Vernetzte mikropartikel und ihre verwendung als arzneiträger
FR2763943B1 (fr) Composes, leur preparation et leur utilisation pour le transfert d'acides nucleiques dans les cellules
BR9305783A (pt) Processo para preparar grânulos dispersiveis em água e grânulos dispersíveis em água
AR016312A1 (es) USO DE UN COMPUESTO DE MEJORAMIENTO DE LA ADINISTRACIoN DE AGENTES TERAPÉUTICOS, COMPOSICIONES FARMACÉUTICAS Y DICHO COMPUESTO.
IT8921243A0 (it) Nuovi geni ibridi funzionali di bacillus thuringiensis ottenuti mediante ricombinazione in vivo.
IL141486A0 (en) Pharmaceutical compositions containing a cd2 binding agent
HK1028615A1 (en) Isolated nona-and decapeptides which bind to hla molecules, and the use thereof
EP1005324A4 (de) Zusammenstezungen zur abgabe von biologischen wirkstoffen und verfahren zu ihrer herstellung
IL149004A0 (en) Magnetic targeted carrier composed of iron and porous materials for the targeted delivery of biologically active agents
MXPA03010261A (es) Metodos para tratar cancer.
HK1025558A1 (en) Optically active 2-aminotetraline, process for its preparation and pharmaceutical compositions containing same, active in preventing and treating septic shock
NZ506406A (en) Compositions comprising Mycobacterium phlei DNA and methods for its use in the treatment of bladder cancer
FR2751967B1 (fr) Agents antipaludeens et antibabesioses et compositions pharmaceutiques les contenant
Quintavalla et al. Differential induction of stromelysin mRNA by bovine articular chondrocytes treated with interferon‐γ and interleukin‐1α
Morris Collagenase and collagenase-inhibitory activity of rabbit articular chondrocytes in response to iron in cell culture.
Newman et al. The effect of changes in cell shape on proteoglycan synthesis in cultured chondrocytes

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application